Liberty Wealth Management LLC Sells 189 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Liberty Wealth Management LLC decreased its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 4.5% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 3,970 shares of the financial services provider’s stock after selling 189 shares during the period. Liberty Wealth Management LLC’s holdings in iShares Biotechnology ETF were worth $545,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Future Financial Wealth Managment LLC acquired a new position in shares of iShares Biotechnology ETF during the 1st quarter worth about $27,000. Bbjs Financial Advisors LLC acquired a new position in iShares Biotechnology ETF during the second quarter valued at approximately $31,000. Pacifica Partners Inc. increased its stake in iShares Biotechnology ETF by 118.2% in the first quarter. Pacifica Partners Inc. now owns 240 shares of the financial services provider’s stock valued at $33,000 after purchasing an additional 130 shares in the last quarter. Crewe Advisors LLC raised its holdings in iShares Biotechnology ETF by 42.9% in the fourth quarter. Crewe Advisors LLC now owns 260 shares of the financial services provider’s stock worth $35,000 after purchasing an additional 78 shares during the period. Finally, YHB Investment Advisors Inc. bought a new position in shares of iShares Biotechnology ETF during the first quarter worth $37,000. 62.45% of the stock is owned by institutional investors.

iShares Biotechnology ETF Stock Performance

IBB opened at $144.53 on Tuesday. iShares Biotechnology ETF has a 12 month low of $111.83 and a 12 month high of $150.17. The company has a fifty day simple moving average of $144.27 and a 200 day simple moving average of $138.08.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.